In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, Lyubomir T., Vu, Binh T., Graves, Bradford, Carvajal, Daisy, Podlaski, Frank, Filipovic, Zoran, Kong, Norman, Kammlott, Ursula, Lukacs, Christine, Klein, Christian, Fotouhi, Nader, Liu, Emily A.·2004·Science
DOI 10.1126/science.1092472

Cited by (1,103)

Items 1,001–1,100 of 1,103

  1. Targeting p53-MDM2-MDMX Loop for Cancer Therapy
    Qi Zhang, Shelya X. Zeng, Hua Lu · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
  2. Small-molecule compounds target paraptosis to improve cancer therapy
    Yujia Wang, Xiang Wen, Nan Zhang, Lian Wang, Dan Hao, Xian Li Jiang, Gu He · 2019 · Biomedicine & Pharmacotherapy
  3. Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines
    Yuanyuan Li, David M. Umbach, J.M. Krahn, Igor Shats, Xiaoling Li, Leping Li · 2021 · BMC Genomics
  4. N-alkylated oligoamide α-helical proteomimetics
    Frederick Campbell, Jeffrey P. Plante, Thomas A. Edwards, Stuart L. Warriner, Andrew John Wilson · 2010 · Organic & Biomolecular Chemistry
  5. Regulation of Metabolic Activity by p53
    Flöter, Jessica, Kaymak, Irem, Schulze, Almut · 2017 · Metabolites
  6. Small molecule modulators of protein-protein interactions: selected case studies
    Aeluri, Madhu, Chamakuri, Srinivas, Dasari, Bhanudas, Guduru, Shiva Krishna Reddy, Jimmidi, Ravikumar, Jogula, Srinivas, Arya, Prabhat · 2014 · Chemical Reviews
  7. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
    Costa, Barbara, Bendinelli, Sara, Gabelloni, Pamela, Da Pozzo, Eleonora, Daniele, Simona, Scatena, Fabrizio, Vanacore, Renato, Campiglia, Pietro, Bertamino, Alessia, Gomez-Monterrey, Isabel et al. · 2013 · PLoS ONE
  8. The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
    Kojima, Kensuke, Burks, Jared K., Arts, Janine, Andreeff, Michael · 2010 · Molecular Cancer Therapeutics
  9. Translational approaches targeting the p53 pathway for anti‐cancer therapy
    Essmann, Frank, Schulze‐Osthoff, Klaus · 2012 · British Journal of Pharmacology
  10. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
    Valentine, Jane M, Kumar, Sonia, Moumen, Abdeladim · 2011 · BMC Cancer
  11. Development of selective small molecule MDM2 degraders based on nutlin
    Wang, Bo, Wu, Suzhen, Liu, Jin, Yang, Ka, Xie, Haibo, Tang, Weiping · 2019 · European Journal of Medicinal Chemistry
  12. Fasting induces a highly resilient deep quiescent state in muscle stem cells via ketone body signaling
    Benjamin, Daniel I., Both, Pieter, Benjamin, Joel S., Nutter, Christopher W., Tan, Jenna H., Kang, Jengmin, Machado, Leo A., Klein, Julian D.D., de Morree, Antoine, Kim, Soochi et al. · 2022 · Cell Metabolism
  13. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
    Agathanggelou, Angelo, Smith, Edward, Davies, Nicholas J., Kwok, Marwan, Zlatanou, Anastasia, Oldreive, Ceri E., Mao, Jingwen, Da Costa, David, Yadollahi, Sina, Perry, Tracey et al. · 2017 · Blood
  14. The regulation of MDM2 by multisite phosphorylation—opportunities for molecular-based intervention to target tumours?
    Meek, David W., Hupp, Ted R. · 2010 · Seminars in Cancer Biology
  15. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
    Berberich, Anne, Kessler, Tobias, Thomé, Carina M., Pusch, Stefan, Hielscher, Thomas, Sahm, Felix, Oezen, Iris, Schmitt, Lara-Marie, Ciprut, Sara, Hucke, Nanina et al. · 2019 · Clinical Cancer Research
  16. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
    Deben, Christophe, Wouters, An, de Beeck, Ken Op, van Den Bossche, Jolien, Jacobs, Julie, Zwaenepoel, Karen, Peeters, Marc, Van Meerbeeck, Jan, Lardon, Filip, Rolfo, Christian et al. · 2015 · Oncotarget
  17. Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
    Wang, Shaomeng, Zhao, Yujun, Bernard, Denzil, Aguilar, Angelo, Kumar, Sanjeev · 2012 · Topics in Medicinal Chemistry
  18. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Pairawan, Seyed, Zhao, Ming, Yuca, Erkan, Annis, Allen, Evans, Kurt, Sutton, David, Carvajal, Luis, Ren, Jian-Guo, Santiago, Solimar, Guerlavais, Vincent et al. · 2021 · Breast Cancer Research
  19. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
    Yi, Hanjie, Yan, Xianglei, Luo, Qiuyun, Yuan, Luping, Li, Baoxia, Pan, Wentao, Zhang, Lin, Chen, Haibo, Wang, Jing, Zhang, Yubin et al. · 2018 · Journal of Experimental & Clinical Cancer Research
  20. Loss of Mdm4 Results in p53 -Dependent Dilated Cardiomyopathy
    Xiong, Shunbin, Van Pelt, Carolyn S., Elizondo-Fraire, Ana C., Fernandez-Garcia, Belen, Lozano, Guillermina · 2007 · Circulation
  21. Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma
    Pishas, Kathleen I., Al-Ejeh, Fares, Zinonos, Irene, Kumar, Raman, Evdokiou, Andreas, Brown, Michael P., Callen, David F., Neilsen, Paul M. · 2011 · Clinical Cancer Research
  22. Transcriptional repression of DNA repair genes is a hallmark and a cause of cellular senescence
    Collin, Guillaume, Huna, Anda, Warnier, Marine, Flaman, Jean-Michel, Bernard, David · 2018 · Cell Death & Disease
  23. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
    Her, Nam-Gu, Oh, Jeong-Woo, Oh, Yun Jeong, Han, Suji, Cho, Hee Jin, Lee, Yeri, Ryu, Gyu Ha, Nam, Do-Hyun · 2018 · Cell Death & Disease
  24. Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
    Bang, Scott, Kaur, Sandeep, Kurokawa, Manabu · 2019 · International Journal of Molecular Sciences
  25. Isolating salient variations of interest in single-cell data with contrastiveVI
    Weinberger, Ethan, Lin, Chris, Lee, Su-In · 2023 · Nature Methods
  26. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration
    Zhang, Fan, Tagen, Michael, Throm, Stacy, Mallari, Jeremy, Miller, Laura, Guy, R. Kiplin, Dyer, Michael A., Williams, Richard T., Roussel, Martine F., Nemeth, Katie et al. · 2011 · Drug Metabolism and Disposition
  27. Small molecules targeting protein–protein interactions for cancer therapy
    Wu, Defa, Li, Yang, Zheng, Lang, Xiao, Huan, Ouyang, Liang, Wang, Guan, Sun, Qiu · 2023 · Acta Pharmaceutica Sinica B
  28. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function
    Azmi, Asfar S., Aboukameel, Amro, Banerjee, Sanjeev, Wang, Zhiwei, Mohammad, Momin, Wu, Jack, Wang, Shaomeng, Yang, Dajun, Philip, Philip A., Sarkar, Fazlul H. et al. · 2010 · European Journal of Cancer
  29. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
    Sullivan, Kelly D, Padilla-Just, Nuria, Henry, Ryan E, Porter, Christopher C, Kim, Jihye, Tentler, John J, Eckhardt, S Gail, Tan, Aik Choon, DeGregori, James, Espinosa, Joaquín M · 2012 · Nature Chemical Biology
  30. Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions
    Raj, Monika, Bullock, Brooke N., Arora, Paramjit S. · 2013 · Bioorganic & Medicinal Chemistry
  31. Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
    Wang, Bo, Liu, Jin, Tandon, Ira, Wu, Suzhen, Teng, Peng, Liao, Jianhua, Tang, Weiping · 2021 · European Journal of Medicinal Chemistry
  32. MDM2-Dependent Inhibition of p53 Is Required for Epstein-Barr Virus B-Cell Growth Transformation and Infected-Cell Survival
    Forte, Eleonora, Luftig, Micah A. · 2009 · Journal of Virology
  33. Role of p53 circuitry in tumorigenesis: A brief review
    Niazi, Sarfaraj, Purohit, Madhusudan, Niazi, Javed H. · 2018 · European Journal of Medicinal Chemistry
  34. p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation
    Xia, M, Knezevic, D, Vassilev, L T · 2011 · Oncogene
  35. Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
    Higgins, Brian, Glenn, Kelli, Walz, Antje, Tovar, Christian, Filipovic, Zoran, Hussain, Sazzad, Lee, Edmund, Kolinsky, Kenneth, Tannu, Shahid, Adames, Violeta et al. · 2014 · Clinical Cancer Research
  36. The p53/MDM2/MDMX-targeted therapies – a clinical synopsis
    Jiang, Liren, Zawacka-Pankau, Joanna · 2020 · Cell Death & Disease
  37. CerS6 Is a Novel Transcriptional Target of p53 Protein Activated by Non-genotoxic Stress
    Fekry, Baharan, Jeffries, Kristen A., Esmaeilniakooshkghazi, Amin, Ogretmen, Besim, Krupenko, Sergey A., Krupenko, Natalia I. · 2016 · Journal of Biological Chemistry
  38. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy
    Liao, Guochao, Yang, Deying, Ma, Leilei, Li, Wenwei, Hu, Liqin, Zeng, Liming, Wu, Peng, Duan, Lixin, Liu, Zhongqiu · 2018 · European Journal of Medicinal Chemistry
  39. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
    de Weger, Vincent A., de Jonge, Maja, Langenberg, Marlies H. G., Schellens, Jan H. M., Lolkema, Martijn, Varga, Andrea, Demers, Brigitte, Thomas, Koruth, Hsu, Karl, Tuffal, Gilles et al. · 2019 · British Journal of Cancer
  40. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
    Zhang, Zhuming, Ding, Qingjie, Liu, Jin-Jun, Zhang, Jing, Jiang, Nan, Chu, Xin-Jie, Bartkovitz, David, Luk, Kin-Chun, Janson, Cheryl, Tovar, Christian et al. · 2014 · Bioorganic & Medicinal Chemistry
  41. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
    Wang, Bo, Fang, Liming, Zhao, Hui, Xiang, Tong, Wang, Dechun · 2012 · Acta Biochimica et Biophysica Sinica
  42. On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53
    Bista, Michal, Smithson, David, Pecak, Aleksandra, Salinas, Gabriella, Pustelny, Katarzyna, Min, Jaeki, Pirog, Artur, Finch, Kristin, Zdzalik, Michal, Waddell, Brett et al. · 2012 · PLoS ONE
  43. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
    Weisberg, Ellen, Halilovic, Ensar, Cooke, Vesselina G., Nonami, Atsushi, Ren, Tao, Sanda, Takaomi, Simkin, Irene, Yuan, Jing, Antonakos, Brandon, Barys, Louise et al. · 2015 · Molecular Cancer Therapeutics
  44. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification
    Cornillie, J., Wozniak, A., Li, H., Gebreyohannes, Y. K., Wellens, J., Hompes, D., Debiec-Rychter, M., Sciot, R., Schöffski, P. · 2020 · Clinical and Translational Oncology
  45. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors
    Vaseva, A V, Yallowitz, A R, Marchenko, N D, Xu, S, Moll, U M · 2011 · Cell Death & Disease
  46. HDMX-L Is Expressed from a Functional p53-responsive Promoter in the First Intron of the HDMX Gene and Participates in an Autoregulatory Feedback Loop to Control p53 Activity
    Phillips, Anna, Teunisse, Amina, Lam, Suzanne, Lodder, Kirsten, Darley, Matthew, Emaduddin, Muhammad, Wolf, Anja, Richter, Julia, de Lange, Job, Verlaan-de Vries, Matty et al. · 2010 · Journal of Biological Chemistry
  47. MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers
    Forslund, Ann, Zeng, Zhaoshi, Qin, Li-Xuan, Rosenberg, Shoshana, Ndubuisi, MacKevin, Pincas, Hanna, Gerald, William, Notterman, Daniel A., Barany, Francis, Paty, Philip B. · 2008 · Molecular Cancer Research
  48. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts
    Chargari, Cyrus, Leteur, Celine, Angevin, Eric, Bashir, Tarig, Schoentjes, Bruno, Arts, Janine, Janicot, Michel, Bourhis, Jean, Deutsch, Eric · 2011 · Cancer Letters
  49. p53-mediated heterochromatin reorganization regulates its cell fate decisions.
    Mungamuri, Sathish Kumar, Benson, Erica Kay, Wang, Shaomeng, Gu, Wei, Lee, Sam W, Aaronson, Stuart A · 2012 · Nature Structural & Molecular Biology
  50. P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
    Mahfoudhi, Emna, Lordier, Larissa, Marty, Caroline, Pan, Jiajia, Roy, Anita, Roy, Lydia, Rameau, Philippe, Abbes, Salem, Debili, Najet, Raslova, Hana et al. · 2016 · Oncotarget
  51. Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
    Hoffman-Luca, C. Gianna, Ziazadeh, Daniel, McEachern, Donna, Zhao, Yujun, Sun, Wei, Debussche, Laurent, Wang, Shaomeng · 2015 · Clinical Cancer Research
  52. Role of Mdm4 in drug sensitivity of breast cancer cells
    Lam, S, Lodder, K, Teunisse, A F A S, Rabelink, M J W E, Schutte, M, Jochemsen, A G · 2010 · Oncogene
  53. Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53–MDM2 Interaction and the NF-κB Pathway
    Zhuang, Chunlin, Miao, Zhenyuan, Wu, Yuelin, Guo, Zizhao, Li, Jin, Yao, Jianzhong, Xing, Chengguo, Sheng, Chunquan, Zhang, Wannian · 2014 · Journal of Medicinal Chemistry
  54. Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells
    Ali, Dina, Mohammad, Dara K., Mujahed, Huthayfa, Jonson‐Videsäter, Kerstin, Nore, Beston, Paul, Christer, Lehmann, Sören · 2016 · British Journal of Haematology
  55. Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist
    Wang, Haiyan, Cai, Shanbao, Bailey, Barbara J., Reza Saadatzadeh, M., Ding, Jixin, Tonsing-Carter, Eva, Georgiadis, Taxiarchis M., Zachary Gunter, T., Long, Eric C., Minto, Robert E. et al. · 2017 · Journal of Neurosurgery
  56. Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
    Azmi, Asfar S., Banerjee, Sanjeev, Ali, Shadan, Wang, Zhiwei, Bao, Bin, Beck, Frances W.J., Maitah, Main, Choi, Minsig, Shields, Tony F., Philip, Philip A. et al. · 2011 · Oncotarget
  57. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
    Wade, Mark, Rodewald, Luo Wei, Espinosa, Joaquín M., Wahl, Geoffrey M. · 2008 · Cell Cycle
  58. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping
    Dubbink, Hendrikus J., Hersmus, Remko, Pike, Ashley C. W., Molier, Michel, Brinkmann, Albert O., Jenster, Guido, Trapman, Jan · 2006 · Molecular Endocrinology
  59. MDM2 promotes invasion and metastasis in invasive ductal breast carcinoma by inducing matrix metalloproteinase-9
    Chen, Xiaofeng, Qiu, Jinrong, Yang, Dapeng, Lu, Jianlei, Yan, Caiyun, Zha, Xiaoming, Yin, Yongmei · 2013 · PLoS ONE
  60. Helping the released guardian: Drug combinations for supporting the anticancer activity of HDM2 (MDM2) antagonists
    Kocik, Justyna, Machula, Monika, Wisniewska, Aneta, Surmiak, Ewa, Holak, Tad A., Skalniak, Lukasz · 2019 · Cancers
  61. A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53
    Wong, Jin Huei, Alfatah, Mohammad, Sin, Mei Fang, Sim, Hong May, Verma, Chandra S., Lane, David P., Arumugam, Prakash · 2017 · BMC Biology
  62. PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo
    Parisotto, Maxime, Grelet, Elise, El Bizri, Rana, Dai, Yongyuan, Terzic, Julie, Eckert, Doriane, Gargowitsch, Laetitia, Bornert, Jean-Marc, Metzger, Daniel · 2018 · Journal of Experimental Medicine
  63. Small-molecule correctors and stabilizers to target p53
    Fallatah, Maryam M.J., Law, Fiona V., Chow, Warren A., Kaiser, Peter · 2023 · Trends in Pharmacological Sciences
  64. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
    Sriraman, Anusha, Radovanovic, Marija, Wienken, Magdalena, Najafova, Zeynab, Li, Yizhu, Dobbelstein, Matthias · 2016 · Oncotarget
  65. Small molecules that bind the Mdm2 RING stabilize and activate p53
    Roxburgh, P., Hock, A. K., Dickens, M. P., Mezna, M., Fischer, P. M., Vousden, K. H. · 2012 · Carcinogenesis
  66. Senescence regulation by mTOR
    Dulic, Vjekoslav · 2013 · Methods in Molecular Biology
  67. Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model
    Tonsing-Carter, Eva, Bailey, Barbara J., Saadatzadeh, M. Reza, Ding, Jixin, Wang, Haiyan, Sinn, Anthony L., Peterman, Kacie M., Spragins, Tiaishia K., Silver, Jayne M., Sprouse, Alyssa A. et al. · 2015 · Molecular Cancer Therapeutics
  68. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells
    Zhu, Ningxi, Gu, Lubing, Li, Fengzhi, Zhou, Muxiang · 2008 · Molecular Cancer Therapeutics
  69. Structural and Functional Comparison of the RING Domains of Two p53 E3 Ligases, Mdm2 and Pirh2
    Shloush, Jonathan, Vlassov, John E., Engson, Ian, Duan, Shili, Saridakis, Vivian, Dhe-paganon, Sirano, Raught, Brian, Sheng, Yi, Arrowsmith, Cheryl H. · 2011 · Journal of Biological Chemistry
  70. MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
    Miles, Xanthene, Vandevoorde, Charlot, Hunter, Alistair, Bolcaen, Julie · 2021 · Frontiers in Oncology
  71. Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
    Toure, Momar, Crews, Craig M. · 2016 · Angewandte Chemie
  72. CDK4 inhibition diminishes p53 activation by MDM2 antagonists
    Sriraman, Anusha, Dickmanns, Antje, Najafova, Zeynab, Johnsen, Steven A., Dobbelstein, Matthias · 2018 · Cell Death & Disease
  73. MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
    Laroche, Audrey, Chaire, Vanessa, Algeo, Marie-Paule, Karanian, Marie, Fourneaux, Benjamin, Italiano, Antoine · 2017 · Oncotarget
  74. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells
    Moran, Diarmuid M., Maki, Carl G. · 2010 · Molecular Cancer Therapeutics
  75. Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program
    Kang, Min H., Reynolds, C. Patrick, Kolb, E. Anders, Gorlick, Richard, Carol, Hernan, Lock, Richard, Keir, Stephen T., Maris, John M., Wu, Jianwrong, Lyalin, Dmitry et al. · 2016 · Pediatric Blood & Cancer
  76. Widespread Overexpression of Epitope-Tagged Mdm4 Does Not Accelerate Tumor Formation In Vivo
    De Clercq, Sarah, Gembarska, Agnieszka, Denecker, Geertrui, Maetens, Marion, Naessens, Michael, Haigh, Katharina, Haigh, Jody J., Marine, Jean-Christophe · 2010 · Molecular and Cellular Biology
  77. First BRET‐based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors
    Corbel, Caroline, Wang, Qian, Bousserouel, Hadjira, Hamdi, Amel, Zhang, Bing, Lozach, Olivier, Ferandin, Yoan, Tan, Vincent B. C., Guéritte, Françoise, Colas, Pierre et al. · 2011 · Biotechnology Journal
  78. The roles of MDM2 and MDMX phosphorylation in stress signaling to p53
    Chen, J. · 2012 · Genes & Cancer
  79. Nutlin-3 Affects Expression and Function of Retinoblastoma Protein
    Du, Wei, Wu, Junfeng, Walsh, Erica M., Zhang, Yujun, Chen, Chang Yan, Xiao, Zhi-Xiong Jim · 2009 · Journal of Biological Chemistry
  80. Abnormal MDMX degradation in tumor cells due to ARF deficiency
    Li, X, Gilkes, D, Li, B, Cheng, Q, Pernazza, D, Lawrence, H, Lawrence, N, Chen, J · 2012 · Oncogene
  81. Inhibition of P53-murine double minute 2 (MDM2) interactions with 3,3′-spirocyclopentene oxindole derivatives
    Gicquel, Maxime, Gomez, Catherine, Garcia Alvarez, Maria Concepcion, Pamlard, Olivier, Guérineau, Vincent, Jacquet, Eric, Bignon, Jérôme, Voituriez, Arnaud, Marinetti, Angela · 2018 · Journal of Medicinal Chemistry
  82. Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells
    Carrillo, Alexia M., Hicks, Mellissa, Khabele, Dineo, Eischen, Christine M. · 2015 · Molecular Cancer Research
  83. Resistance acquisition to MDM2 inhibitors
    Cinatl, Jindrich, Speidel, Daniel, Hardcastle, Ian, Michaelis, Martin · 2014 · Biochemical Society Transactions
  84. MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
    Pellot Ortiz, Karolina I., Rechberger, Julian S., Nonnenbroich, Leo F., Daniels, David J., Sarkaria, Jann N. · 2023 · Biomedicines
  85. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death
    Conradt, Laura, Henrich, Annika, Wirth, Matthias, Reichert, Maximilian, Lesina, Marina, Algül, Hana, Schmid, Roland M., Krämer, Oliver H., Saur, Dieter, Schneider, Günter · 2013 · International Journal of Cancer
  86. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities
    Valentin-Vega, Yasmine A., Box, Neil, Terzian, Tamara, Lozano, Guillermina · 2009 · Differentiation
  87. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma
    Phelps, Doris, Bondra, Kathryn, Seum, Star, Chronowski, Christopher, Leasure, Justin, Kurmasheva, Raushan T., Middleton, Steven, Wang, Dian, Mo, Xiaokui, Houghton, Peter J. · 2015 · Pediatric Blood & Cancer
  88. Evidence of Conformational Selection Driving the Formation of Ligand Binding Sites in Protein-Protein Interfaces
    Bohnuud, Tanggis, Kozakov, Dima, Vajda, Sandor · 2014 · PLoS Computational Biology
  89. The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1
    Jones, Richard J., Gu, Dongmin, Bjorklund, Chad C., Kuiatse, Isere, Remaley, Alan T., Bashir, Tarig, Vreys, Veronique, Orlowski, Robert Z. · 2013 · The Journal of Pharmacology and Experimental Therapeutics
  90. Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells
    Sui, X, Shin, S, Zhang, R, Firozi, P F, Yang, L, Abbruzzese, J L, Reddy, S A G · 2009 · Oncogene
  91. Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: a systematic review of the literature
    Pi, L, Rooprai, J, Allan, DS, Atkins, H, Bredeson, C, Fulcher, AJ, Ito, C, Ramsay, T, Shorr, Stanford, WL et al. · 2019 · Leukemia Research
  92. Affinity-based screening of MDM2/MDMX–p53 interaction inhibitors by chemical array: Identification of novel peptidic inhibitors
    Noguchi, Taro, Oishi, Shinya, Honda, Kaori, Kondoh, Yasumitsu, Saito, Tamio, Kubo, Tatsuhiko, Kaneda, Masato, Ohno, Hiroaki, Osada, Hiroyuki, Fujii, Nobutaka · 2013 · Bioorganic & Medicinal Chemistry Letters
  93. RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas
    Obrador-Hevia, Antònia, Martinez-Font, Esther, Felipe-Abrio, Irene, Calabuig-Fariñas, Silvia, Serra-Sitjar, Margalida, López-Guerrero, José Antonio, Ramos, Rafael, Alemany, Regina, Martín-Broto, Javier · 2015 · Cancer Investigation
  94. E3 ubiquitin ligases and human papillomavirus-induced carcinogenesis
    Lou, Zhifeng, Wang, Sheng · 2014 · Journal of International Medical Research
  95. Protecting the genome from mdm2 and mdmx
    Melo, A. N., Eischen, C. M. · 2012 · Genes & Cancer
  96. A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
    Rendo, Veronica, Lee, Eudocia Q., Bossi, Connor, Khuu, Nicholas, Rudek, Michelle A., Pal, Sangita, Azazmeh, Narmen, Rashid, Rumana, Lin, Jia-Ren, Cusick, Margaret et al. · 2025 · Science Translational Medicine
  97. HMG-CoA Reductase Inhibitor Statins Activate the Transcriptional Activity of p53 by Regulating the Expression of TAZ
    Miyajima, Chiharu, Hayakawa, Yurika, Inoue, Yasumichi, Nagasaka, Mai, Hayashi, Hidetoshi · 2022 · Pharmaceuticals
  98. Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts
    Lenos, Kristiaan, de Lange, Job, Teunisse, Amina FAS, Lodder, Kirsten, Verlaan-de Vries, Matty, Wiercinska, Eliza, van der Burg, Marja JM, Szuhai, Karoly, Jochemsen, Aart G · 2011 · Molecular Cancer
  99. What do we need to know and understand about p53 to improve its clinical value?
    Salomao, Norman, Karakostis, Konstantinos, Hupp, Ted, Vollrath, Friz, Vojtesek, Borivoj, Fahraeus, Robin · 2021 · The Journal of Pathology
  100. Differential mechanisms involved in RG-7388 and Nutlin-3 induced cell death in SJSA-1 osteosarcoma cells
    Natarajan, Umamaheswari, Venkatesan, Thiagarajan, Dhandayuthapani, Sivanesan, Dondapatti, Priya, Rathinavelu, Appu · 2020 · Cellular Signalling